Search alternatives:
decrease therapeutic » increased therapeutic (Expand Search), degrader therapeutics (Expand Search), great therapeutic (Expand Search)
acid resistance » acquired resistance (Expand Search), lactam resistance (Expand Search), crack resistance (Expand Search)
a therapeutic » _ therapeutic (Expand Search), _ therapeutics (Expand Search), new therapeutic (Expand Search)
decrease acid » decreased acadm (Expand Search), decrease i (Expand Search)
Showing 21 - 40 results of 28,979 for search '(( ((decrease therapeutic) OR (a therapeutic)) research ) OR ( decrease acid resistance ))', query time: 0.94s Refine Results
  1. 21
    Figure S4 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes

    Figure S4 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes by Pauline J. van der Watt (15068109)

    Published 2023
    Save to List
    Saved in:
  2. 22
    Figure 4 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma

    Figure 4 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma by Khaled Mohamed Nassar (19810317)

    Published 2025
    Save to List
    Saved in:
  3. 23
    Figure 2 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma

    Figure 2 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma by Khaled Mohamed Nassar (19810317)

    Published 2025
    Save to List
    Saved in:
  4. 24
    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  5. 25
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  6. 26
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  7. 27
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  8. 28
    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  9. 29
    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  10. 30
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  11. 31
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  12. 32
    Supplemental Table 2 Phosphokinase Array from Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma

    Supplemental Table 2 Phosphokinase Array from Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocar... by Brittany L. Allen-Petersen (14935217)

    Published 2023
    Save to List
    Saved in:
  13. 33
    Transepithelial resistance of NHBE decreases significantly after PAA exposure.

    Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

    Published 2025
    Save to List
    Saved in:
  14. 34
    Supplemental Table 1 Kinase Inhibitor Screen from Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma

    Supplemental Table 1 Kinase Inhibitor Screen from Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Aden... by Brittany L. Allen-Petersen (14935217)

    Published 2023
    Save to List
    Saved in:
  15. 35
    Supplementary Data S1 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

    Supplementary Data S1 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance by Kristen Jensen-Pergakes (15090247)

    Published 2023
    Save to List
    Saved in:
  16. 36
    Supplementary Data S2 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

    Supplementary Data S2 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance by Kristen Jensen-Pergakes (15090247)

    Published 2023
    Save to List
    Saved in:
  17. 37
    Supplementary Data S3 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

    Supplementary Data S3 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance by Kristen Jensen-Pergakes (15090247)

    Published 2023
    Save to List
    Saved in:
  18. 38
    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment

    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment by Dimitrios N. Sidiropoulos (8812874)

    Published 2023
    Save to List
    Saved in:
  19. 39
    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment

    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment by Dimitrios N. Sidiropoulos (8812874)

    Published 2023
    Save to List
    Saved in:
  20. 40
    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment

    Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2<sup>+</sup> Breast Tumor Microenvironment by Dimitrios N. Sidiropoulos (8812874)

    Published 2023
    Save to List
    Saved in:

Search Tools: